Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Coarse

Showing results (1-10 of 3) with videos related to

Pageof 1
Sort By:
Hospital Formulary|August 8, 1986
Adverse drug reaction reporting system: developing a well-monitored programD J Kilarski, B Ziegler, J Coarse, et al.
Alimentary Pharmacology & Therapeutics|November 22, 2017
Exposure-response relationship of certolizumab pegol induction and maintenance therapy in patients with Crohn's diseaseN Vande Casteele, B G Feagan, S Vermeire, et al.
Alimentary Pharmacology & Therapeutics|June 3, 2015
Clinical and demographic characteristics predictive of treatment outcomes for certolizumab pegol in moderate to severe Crohn's disease: analyses from the 7-year PRECiSE 3 studyW J Sandborn, G Y Melmed, D P B McGovern, et al.
Pageof 1

Showing results (1-10 of 3) with videos related to

Sort By:
Pageof 1
Hospital Formulary|August 8, 1986
Adverse drug reaction reporting system: developing a well-monitored programD J Kilarski, B Ziegler, J Coarse, et al.
Alimentary Pharmacology & Therapeutics|November 22, 2017
Exposure-response relationship of certolizumab pegol induction and maintenance therapy in patients with Crohn's diseaseN Vande Casteele, B G Feagan, S Vermeire, et al.
Alimentary Pharmacology & Therapeutics|June 3, 2015
Clinical and demographic characteristics predictive of treatment outcomes for certolizumab pegol in moderate to severe Crohn's disease: analyses from the 7-year PRECiSE 3 studyW J Sandborn, G Y Melmed, D P B McGovern, et al.
Pageof 1